The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy

Drug Discovery Today

Volumn 16, Issue 5-6, 2011, Pages 219-228

  Van Der Meel, Roy ^a   Symons, Marc H ^b   Kudernatsch, Robert ^c   Kok, Robbert J ^a   Schiffelers, Raymond M ^a   Storm, Gert ^a   Gallagher, William M ^d   Byrne, Annette T ^e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ANGIOGENESIS INHIBITOR; EHT 1864; FASUDIL; H1152P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPA 3; MARIMASTAT; MLS 000532223; PACLITAXEL; PAK1; PEC 3758309; PF 3758309; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN CDC42; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; SMALL MOLECULE INHIBITOR; TRANSCRIPTION FACTOR PITX3; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; WISKOSTATIN; Y 32885; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BASEMENT MEMBRANE; BLOOD VESSEL PERMEABILITY; BRAIN VASOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; DRUG BINDING; DRUG INHIBITION; DRUG TARGETING; HUMAN; METASTASIS; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952455505     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.01.005     Document Type: Review

References (87)

1. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
2. R.S. Kerbel Tumor angiogenesis N. Engl. J. Med. 358 2008 2039 2049 (Pubitemid 351656458)
3. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 3 2003 401 410 (Pubitemid 37328844)
4. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr. Rev. 25 2004 581 611 (Pubitemid 39099316)
5. A.K. Olsson VEGF receptor signalling - in control of vascular function Nat. Rev. Mol. Cell Biol. 7 2006 359 371
6. S.J. Heasman, and A.J. Ridley Mammalian Rho GTPases: new insights into their functions from in vivo studies Nat. Rev. Mol. Cell Biol. 9 2008 690 701
7. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
8. L.B. Saltz Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J. Clin. Oncol. 26 2008 2013 2019
9. J.M. Ebos Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
10. M. Paez-Ribes Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
11. A.Y. Chan Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion Oncogene 24 2005 7821 7829 (Pubitemid 41715188)
12. L. Wang, and Y. Zheng Cell type-specific functions of Rho GTPases revealed by gene targeting in mice Trends Cell Biol. 17 2007 58 64 (Pubitemid 46199180)
13. B.A. Bryan, and P.A. D'Amore What tangled webs they weave: Rho-GTPase control of angiogenesis Cell Mol. Life Sci. 64 2007 2053 2065 (Pubitemid 350092415)
14. L. Lamalice Endothelial cell migration during angiogenesis Circ. Res. 100 2007 782 794 (Pubitemid 46555683)
15. C.M. Beckers Driving Rho GTPase activity in endothelial cells regulates barrier integrity Thromb. Haemost. 103 2010 40 55
16. E. Monaghan-Benson, and K. Burridge The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species J. Biol. Chem. 284 2009 25602 25611
17. B.A. Bryan RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis Faseb J. 24 2010 3186 3195
18. E. Ispanovic Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation Am. J. Physiol. Cell Physiol. 295 2008 600 610
19. I. Abecassis RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion Exp. Cell Res. 291 2003 363 376 (Pubitemid 37485724)
20. M. Raftopoulou, and A. Hall Cell migration: Rho GTPases lead the way Dev. Biol. 265 2004 23 32 (Pubitemid 38018819)
21. G.P. van Nieuw Amerongen Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro Arterioscler. Thromb. Vasc. Biol. 23 2003 211 217 (Pubitemid 36231930)
22. W. Tan An essential role for Rac1 in endothelial cell function and vascular development Faseb J. 22 2008 1829 1838 (Pubitemid 351811460)
23. M.K. Garnaas Syx, a RhoA guanine exchange factor, is essential for angiogenesis in vivo Circ. Res. 103 2008 710 716
24. M.A. Engelse Differential gene expression analysis of tubule forming and non-tubule forming endothelial cells: CDC42GAP as a counter-regulator in tubule formation Angiogenesis 11 2008 153 167
25. K. Hirano A critical period requiring Rho proteins for cell cycle progression uncovered by reversible protein transduction in endothelial cells FEBS Lett. 570 2004 149 154 (Pubitemid 38900973)
26. J.Y. Pille Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo Mol. Ther. 11 2005 267 274
27. M.L. Iruela-Arispe, and G.E. Davis Cellular and molecular mechanisms of vascular lumen formation Dev. Cell 16 2009 222 231
28. M. Kamei Endothelial tubes assemble from intracellular vacuoles in vivo Nature 442 2006 453 456 (Pubitemid 44264794)
29. B. Strilic The molecular basis of vascular lumen formation in the developing mouse aorta Dev. Cell 17 2009 505 515
30. J. Kroll Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis Am. J. Physiol. Heart Circ. Physiol. 296 2009 893 899
31. G. D'Amico Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent PLoS One 5 2010 e9766
32. R. Karlsson Rho GTPase function in tumorigenesis Biochim. Biophys. Acta 1796 2009 91 98
33. P. Friedl, and K. Wolf Plasticity of cell migration: a multiscale tuning model J. Cell Biol. 188 2010 11 19
34. V. Sanz-Moreno Rac activation and inactivation control plasticity of tumor cell movement Cell 135 2008 510 523
35. G. Gadea DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells Curr. Biol. 18 2008 1456 1465
36. A. Hakem RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis Genes Dev. 19 2005 1974 1979 (Pubitemid 41247955)
37. S. Zavarella Role of Rac1-regulated signaling in medulloblastoma invasion. Laboratory investigation J. Neurosurg. Pediatr. 4 2009 97 104
38. B. Salhia The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma Am. J. Pathol. 173 2008 1828 1838
39. R.A. Bartolome Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity Cancer Res. 68 2008 8221 8230
40. C.G. Kleer RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck Clin. Cancer Res. 12 2006 4485 4490 (Pubitemid 44297796)
41. T. Kamai Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer BMC Cancer 10 2010 164
42. P.R. Molli PAK signaling in oncogenesis Oncogene 28 2009 2545 2555
43. L. Van Aelst, and C. D'Souza-Schorey Rho GTPases and signaling networks Genes Dev. 11 1997 2295 2322 (Pubitemid 27408529)
44. M. Dong Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases Drug Discov. Today 15 2010 622 629
45. L. Yin Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Mol. Cancer Ther. 6 2007 1517 1525 (Pubitemid 46954018)
46. H. Ying The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models Mol. Cancer Ther. 5 2006 2158 2164 (Pubitemid 44530451)
47. A.V. Somlyo Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants Faseb J. 17 2003 223 234 (Pubitemid 36164392)
48. Y. Sasaki The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway Pharmacol. Ther. 93 2002 225 232 (Pubitemid 34615563)
49. Y. Gao Rational design and characterization of a Rac GTPase-specific small molecule inhibitor Proc. Natl. Acad. Sci. U. S. A. 101 2004 7618 7623 (Pubitemid 38658078)
50. E. Sulpice Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells Biol. Cell 101 9 2009 525 539
51. C.R. Evelyn CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling Mol. Cancer Ther. 6 2007 2249 2260 (Pubitemid 47294753)
52. W. Koh Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling J. Cell Sci. 121 2008 989 1001 (Pubitemid 351639418)
53. B.W. Murray Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth Proc. Natl. Acad. Sci. U. S. A. 107 2010 9446 9451
54. A. Shutes Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases J. Biol. Chem. 282 2007 35666 35678 (Pubitemid 350277149)
55. S.W. Deacon An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase Chem. Biol. 15 2008 322 331 (Pubitemid 351508427)
56. J.R. Peterson Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation Nat. Struct. Mol. Biol. 11 2004 747 755 (Pubitemid 39014500)
57. J. Zhang Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
58. Z. Surviladze Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay J. Biomol. Screen 15 2010 10 20
59. N. Bouquier A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway Chem. Biol. 16 2009 657 666
60. T.A. Garrett VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2 Exp. Cell Res. 313 2007 3285 3297 (Pubitemid 47284065)
61. J.Y. Pille Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer Hum. Gene Ther. 17 2006 1019 1026
62. P.A. Konstantinopoulos Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets Nat. Rev. Drug Discov. 6 2007 541 555 (Pubitemid 47019443)
63. H.J. Park 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA Circ. Res. 91 2002 143 150
64. Y. Kureishi The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat. Med. 6 2000 1004 1010
65. M. Katsumoto Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis Circ. J. 69 2005 1547 1555 (Pubitemid 41743974)
66. S.A. Glynn The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells BMC Cancer 8 2008 9
67. K. Hashimoto Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells Biochem. Biophys. Res. Commun. 354 2007 478 484 (Pubitemid 46161348)
68. C. Scavelli Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma Mol. Cancer Ther. 6 2007 3256 3262
69. C.Y. Wang Pleiotropic effects of statin therapy: molecular mechanisms and clinical results Trends Mol. Med. 14 2008 37 44
70. D.M. Brantley-Sieders Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo Mol. Cancer Res. 7 2009 615 623
71. Y. Xue Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation Int. J. Cancer 118 2006 2965 2972
72. M. Dokmanovic Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer Mol. Cancer Ther. 8 2009 1557 1569
73. R. Gutt Statin use and risk of prostate cancer recurrence in men treated with radiation therapy J. Clin. Oncol. 28 2010 2653 2659
74. M. Gnant Endocrine therapy plus zoledronic acid in premenopausal breast cancer N. Engl. J. Med. 360 2009 679 691
75. K.L. Rossman GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors Nat. Rev. Mol. Cell Biol. 6 2005 167 180 (Pubitemid 40215811)
76. J.F. Cote, and K. Vuori GEF what? Dock180 and related proteins help Rac to polarize cells in new ways Trends Cell Biol. 17 2007 383 393 (Pubitemid 47375099)
77. J. Tcherkezian, and N. Lamarche-Vane Current knowledge of the large RhoGAP family of proteins Biol. Cell 99 2007 67 86 (Pubitemid 46242033)
78. C. DerMardirossian, and G.M. Bokoch GDIs: central regulatory molecules in Rho GTPase activation Trends Cell Biol. 15 2005 356 363 (Pubitemid 40943524)
79. X.R. Bustelo GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo Bioessays 29 2007 356 370 (Pubitemid 46597867)
80. R.D. Meyer The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2/FLK-1 regulates its autophosphorylation and activation of signaling molecules J. Biol. Chem. 277 2002 27081 27087 (Pubitemid 34951721)
81. J. Gavard, and J.S. Gutkind VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin Nat. Cell Biol. 8 2006 1223 1234 (Pubitemid 44660587)
82. R.D. Meyer IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis PLoS One 3 2008 e3848
83. M. Yamaoka-Tojo IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation Circ. Res. 95 2004 276 283 (Pubitemid 39056288)
84. M. Yamaoka-Tojo IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis Arterioscler. Thromb. Vasc. Biol. 26 2006 1991 1997 (Pubitemid 44253779)
85. L. Lamalice Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38 Oncogene 23 2004 434 445 (Pubitemid 38174998)
86. L. Lamalice Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF J. Biol. Chem. 281 2006 34009 34020 (Pubitemid 46036610)
87. R. Bhattacharya Distinct role of PLCbeta3 in VEGF-mediated directional migration and vascular sprouting J. Cell Sci. 122 2009 1025 1034